Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review

References

• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4(4):355–366. doi: 10.1016/j.crohns.2010.04.004.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30. doi: 10.1016/j.autrev.2013.06.002.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease—algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51. doi: 10.1111/apt.13445.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760–767. doi: 10.1038/ajg.2008.88.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21(1):182–197. doi: 10.1097/MIB.0000000000000202.
   PubMed Web of Science ®Google Scholar
• Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52(4):669–681. doi: 10.1111/apt.15921.
   PubMed Web of Science ®Google Scholar
• Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15. doi: 10.1111/apt.14075.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6(8):461–470. doi: 10.1038/nrneph.2010.71.
   PubMed Web of Science ®Google Scholar
• Simpson N, Seenan JP, Patel R, et al. Acute interstitial nephritis secondary to vedolizumab. BMJ Case Rep. 2021;14(11):e243568. doi: 10.1136/bcr-2021-243568.
   PubMedGoogle Scholar
• Subhaharan D, Ramaswamy PK, Francisco S, et al. Vedolizumab-Induced acute interstitial nephritis in ulcerative colitis. ACG Case Rep J. 2022;9(6):e00788. doi: 10.14309/crj.0000000000000788.
   PubMed Web of Science ®Google Scholar
• Bailly E, Von Tokarski F, Beau-Salinas F, et al. Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis. 2018;71(1):142–145. doi: 10.1053/j.ajkd.2017.08.008.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–799. doi: 10.1016/j.recesp.2021.06.016.
   PubMed Web of Science ®Google Scholar
• VigiBase. World Health Organization (WHO). [cited 2023 Apr 4]. Available at www.vigiaccess.org
   Google Scholar
• Swedish Medical Products Agency Department of Drug Safety, database BiSi(biverkningsrapporter och signaler). Contact through email 2023 Apr 1.
   Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. The Ottawa Hospital Research Institute. [cited 2022 Dec 6]. Available at https://www.ohri.ca/Programs/clinical_epidemiology/oxford.asp
   Google Scholar
• The Merck Index Online. Royal society of chemistry. [cited 2023 Nov 5]. Available at: The Merck Index Online - chemicals, drugs and biologicals (rsc.org).
   Google Scholar
• World Health Organization (WHO)-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Available at http://www.who-umc.org/Graphics/24734.pdf
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi: 10.1038/clpt.1981.154.
   PubMed Web of Science ®Google Scholar
• Shukla AK, Jhaj R, Misra S, et al. Agreement between WHO-UMC causality scale and the Naranjo algorithm for causality assessment of adverse drug reactions. J Family Med Prim Care. 2021;10(9):3303–3308. doi: 10.4103/jfmpc.jfmpc_831_21.
   PubMedGoogle Scholar
• Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice—a nationwide consecutive German Cohort Study. Aliment Pharmacol Ther. 2016;43(10):1090–1102. doi: 10.1111/apt.13594.
   PubMed Web of Science ®Google Scholar
• Beau-Salinas F, Von Tokarski F, Rousseau G, et al. First case of tubulointerstitial nephropathy associated with vedolizumab. Fundam Clin Pharmacol. 2017;31:61.
   Web of Science ®Google Scholar
• Biancone L, Annese V, Ardizzone S, et al. Safety of treatments for inflammatory bowel disease: clinical practice guidelines of the italian group for the study of inflammatory bowel disease (IG-IBD). Dig Liver Dis. 2017;49(4):338–358. doi: 10.1016/j.dld.2017.01.141.
   PubMedGoogle Scholar
• Burgevin A, Caron B, Sasson A, et al. Comparative safety of ustekinumab and vedolizumab in older patients with inflammatory bowel disease: a bicentric cohort study. J Clin Med. 2022;11(23):6967. doi: 10.3390/jcm11236967.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Bhayat F, Blake A, et al. The safety profile of vedolizumab in ulcerative colitis and Crohn’s disease: 4 years of global post-marketing data. J Crohns Colitis. 2020;14(2):192–204. doi: 10.1093/ecco-jcc/jjz137.
   PubMed Web of Science ®Google Scholar
• Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–2431. doi: 10.1097/MIB.0000000000000918.
   PubMed Web of Science ®Google Scholar
• Cordesse A, Delbet J-D, Lemoine A, et al. Prevalence and etiologies of renal and urinary manifestations in a large cohort of children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2022;76(3):331–337. doi: 10.1097/MPG.0000000000003682.
   PubMed Web of Science ®Google Scholar
• Dalal RS, McClure EL, Marcus J, et al. Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-naïve patients with ulcerative colitis. Dig Dis Sci. 2023;68(1):223–232. doi: 10.1007/s10620-022-07472-1.
   PubMed Web of Science ®Google Scholar
• Dincer MT, Dincer ZT, Bakkaloglu OK, et al. Renal manifestations in inflammatory bowel disease: a cohort study during the biologic era. Med Sci Monit. 2022;28:e936497. doi: 10.12659/MSM.936497.
   PubMed Web of Science ®Google Scholar
• Fang S, Song Y, Zhang C, et al. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr. 2022;22(1):175. doi: 10.1186/s12887-022-03229-x.
   PubMed Web of Science ®Google Scholar
• Feagan B, Leach T, Milch C, et al. P-0025: emerging safety profile of vedolizumab: a novel, selective integrin inhibitor for the treatment of IBD. Inflamm Bowel Dis. 2009;15: S12. doi: 10.1097/00054725-200912002-00033.
   Web of Science ®Google Scholar
• Grossi V, Hyams JS. The safety of treatment options for pediatric Crohn’s disease. Expert Opin Drug Saf. 2016;15(10):1383–1390. doi: 10.1080/14740338.2016.1203418.
   PubMed Web of Science ®Google Scholar
• Jahan S, Xu A, Danner R, et al. Acute interstitial nephritis with inflammatory bowel disease. Nephrology. 2022;27:69–70.
   Web of Science ®Google Scholar
• Kepley A, Marino D, DeCross A. P053 interstitial nephritis from IBD: complicated conclusions. Am J Gastroenterol. 2021;116(Suppl 1):S14–S14. doi: 10.14309/01.ajg.0000798812.13521.04.
   PubMedGoogle Scholar
• Khellaf R, Pietrement C, Pons A. Renal involvement in chronic inflammatory bowel diseases: a series of pediatric cases in France. Pediatr Nephrol. 2022;37:2850.
   Web of Science ®Google Scholar
• Kotze P, Ma C, Almutairdi A, et al. A115 clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s disease. J Can Assoc Gastroenterol. 2018;1(suppl_2):175–176. doi: 10.1093/jcag/gwy009.115.
   Google Scholar
• Loftus EV, Jr., Colombel JF, Feagan BG, et al. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017;11:400–411.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Orlando R, Fries W, et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis. 2018;50(7):675–681. doi: 10.1016/j.dld.2018.02.013.
   PubMedGoogle Scholar
• Martí Romero L, Peño Muñoz L, Martínez Escapa V, et al. Use of teduglutide for short bowel syndrome and Crohn’s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy. Rev Esp Enferm Dig. 2023;115:331–332.
   PubMed Web of Science ®Google Scholar
• Muzib A, Parikh R, Bijol V, et al. Vedolizumab-induced acute interstitial nephritis and acute tubular necrosis. J Am Soc Nephrol. 2020;31:688.
   Google Scholar
• O’Leary C, Wong D, Wilson GJ. Vedolizumab induced acute interstitial nephritis: a case of failed steroid prophylaxis. Nephrology. 2022;27:72.
   Web of Science ®Google Scholar
• Oikonomou KA, Kapsoritakis AN, Stefanidis I, et al. Drug-induced nephrotoxicity in inflammatory bowel disease. Nephron Clin Pract. 2011;119(2):c89–c94; discussion c96. doi: 10.1159/000326682.
   PubMedGoogle Scholar
• Ollech JE, Dwadasi S, Rai V, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020;51(6):637–643. doi: 10.1111/apt.15616.
   PubMed Web of Science ®Google Scholar
• Peverelle M, Mills CD, Testro A, et al. Real world outcomes of vedolizumab for inflammatory bowel disease post liver transplantation. Gastroenterology. 2018;154(6):S-845. doi: 10.1016/S0016-5085(18)32865-8.
   Web of Science ®Google Scholar
• Dhandayuthapani R, Zouzo V, Cameron F. Outcomes after using vedolizumab in paediatric inflammatory bowel disease in a tertiary centre, over a 3 year period. 6th World Congress of PGHAN: Abstracts. J Pediatr Gastroenterol Nutr. 2021;72:223–224.
   Google Scholar
• Roberti R, Iannone LF, Palleria C, et al. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin. 2020;36(9):1457–1463. doi: 10.1080/03007995.2020.1786681.
   PubMed Web of Science ®Google Scholar
• Sattler L, Hanauer SB, Malter L. Immunomodulatory agents for treatment of patients with inflammatory bowel disease (review safety of anti-TNF, anti-integrin, anti IL-12/23, JAK inhibition, sphingosine 1-phosphate receptor modulator, azathioprine/6-MP and methotrexate). Curr Gastroenterol Rep. 2021;23(12):30. doi: 10.1007/s11894-021-00829-y.
   PubMedGoogle Scholar
• Yin W, Zhang PL. Vedolizumab, a monoclonal antibody for treating Crohn disease, can cause t-cell-mediated interstitial nephritis and CKD. J Am Soc Nephrol. 2019;30:155.
   Google Scholar
• Zhang PL, Pancioli T, Li W, et al. Electron microscopic findings can support multiple etiologies of nephrotoxicity in renal tubules. Ultrastruct Pathol. 2020;44(4–6):481–488. doi: 10.1080/01913123.2020.1839152.
   PubMed Web of Science ®Google Scholar
• Ladd AHM, Scott FI, Grace R, et al. Safety of vedolizumab in inflammatory bowel disease patients: real world experience from a large university practice. Tu 1918. AGA Abstracts. 2016;150(4):S977. doi: 10.1016/S0016-5085(16)33311-X.
   Google Scholar
• Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49(7):873–879. doi: 10.1111/apt.15177.
   PubMed Web of Science ®Google Scholar
• Allamneni C, Venkata K, Yun H, et al. Comparative effectiveness of vedolizumab vs. infliximab induction therapy in ulcerative colitis: experience of a real-world cohort at a tertiary inflammatory bowel disease center. Gastroenterol. Res. 2018;11(1):41–45. doi: 10.14740/gr934w.
   PubMed Web of Science ®Google Scholar
• Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients With inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–1601.e2. doi: 10.1016/j.cgh.2016.02.016.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–321. doi: 10.1111/apt.14167.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-Centre cohort study. Aliment Pharmacol Ther. 2019;50(1):40–53. doi: 10.1111/apt.15294.
   PubMed Web of Science ®Google Scholar
• Asscher VER, Biemans VBC, Pierik MJ, et al. Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment Pharmacol Ther. 2020;52(8):1366–1376. doi: 10.1111/apt.16073.
   PubMed Web of Science ®Google Scholar
• Christensen B, Goeppinger S, Colman R. Post-marketing experience of vedolizumab for IBD: the University of Chicago experience. Barcelona: ECCO; 2015. Abstract.
   Google Scholar
• Biemans VBC, van der Woude CJ, Dijkstra G, et al. Vedolizumab for inflammatory bowel disease: two-year results of the initiative on Crohn and colitis (ICC) registry, a nationwide prospective observational cohort study: ICC Registry—vedolizumab. Clin Pharmacol Ther. 2020;107(5):1189–1199. doi: 10.1002/cpt.1712.
   PubMed Web of Science ®Google Scholar
• Bressler B, Yarur A, Silverberg MS, et al. Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: results from the EVOLVE study. J Crohns Colitis. 2021;15(10):1694–1706. doi: 10.1093/ecco-jcc/jjab058.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Ricart E, et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2018;48(8):839–851. doi: 10.1111/apt.14930.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851. doi: 10.1136/gutjnl-2015-311079.
   PubMed Web of Science ®Google Scholar
• Cross RK, Chiorean M, Vekeman F, et al. Assessment of the real-world safety profile of vedolizumab using the United States food and drug administration adverse event reporting system. PLoS One. 2019;14(12):e0225572. doi: 10.1371/journal.pone.0225572.
   PubMed Web of Science ®Google Scholar
• Davis R, McParland P, Dodd S, et al. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis. Eur J Gastroenterol Hepatol. 2019;31(6):661–667. doi: 10.1097/MEG.0000000000001395.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The Real-World effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results From the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–1155. doi: 10.1038/ajg.2016.236.
   PubMed Web of Science ®Google Scholar
• Eriksson C, Rundquist S, Lykiardopoulos V, et al. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol. 2021;14:17562848211023386. doi: 10.1177/17562848211023386.
   Web of Science ®Google Scholar
• Fabiszewska S, Derda E, Szymanska E, et al. Safety and effectiveness of vedolizumab for the treatment of pediatric patients with very early onset inflammatory bowel diseases. J Clin Med. 2021;10(13):2997.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rubin DT, Danese S, et al. Efficacy of vedolizumab induction and maintenance therapy in patients With ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239.e5. doi: 10.1016/j.cgh.2016.08.044.
   PubMed Web of Science ®Google Scholar
• Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, et al. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr. 2021;180(9):3029–3038. doi: 10.1007/s00431-021-04063-6.
   PubMed Web of Science ®Google Scholar
• Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2015;14(9):1473–1479. doi: 10.1517/14740338.2015.1063612.
   PubMed Web of Science ®Google Scholar
• Hajjat TM, Mosha M, Whaley KG, et al. Vedolizumab experience in children and adolescents with inflammatory bowel disease: a multicenter observational study. Crohns Colitis. 2021;360:3:otab039.
   Google Scholar
• Helwig U, Mross M, Schubert S, et al. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a german retrospective chart review. BMC Gastroenterol. 2020;20(1):211. doi: 10.1186/s12876-020-01332-w.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Ron Y, Avni-Biron I, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the israeli Real-World experience. Inflamm Bowel Dis. 2017;23(3):404–408. doi: 10.1097/MIB.0000000000001039.
   PubMed Web of Science ®Google Scholar
• Ledder O, Assa A, Levine A, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017;11(10):1230–1237. doi: 10.1093/ecco-jcc/jjx082.
   PubMed Web of Science ®Google Scholar
• Lukin D, Faleck D, Xu R, et al. Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis. Clin Gastroenterol Hepatol. 2022;20(1):126–135. doi: 10.1016/j.cgh.2020.10.003.
   PubMed Web of Science ®Google Scholar
• Meserve J, Aniwan S, Koliani-Pace JL, et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17(8):1533–1540.e2. doi: 10.1016/j.cgh.2018.09.035.
   PubMed Web of Science ®Google Scholar
• Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113(9):1345. doi: 10.1038/s41395-018-0162-0.
   PubMed Web of Science ®Google Scholar
• Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691–1699. doi: 10.1097/MIB.0b013e318281f538.
   PubMed Web of Science ®Google Scholar
• Patel H, Latremouille-Viau D, Burne R, et al. Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease. Crohn’s Colitis 360. 2019;1(2):otz022. doi: 10.1093/crocol/otz022.
   Google Scholar
• Rundquist S, Sachs MC, Eriksson C, et al. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Aliment Pharmacol Ther. 2021;53(4):471–483. doi: 10.1111/apt.16193.
   PubMed Web of Science ®Google Scholar
• Samaan MA, Pavlidis P, Johnston E, et al. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8(3):196–202. doi: 10.1136/flgastro-2016-100720.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, Jr., et al. Vedolizumab versus adalimumab for moderate-to-Severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226. doi: 10.1056/NEJMoa1905725.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064. doi: 10.1007/s00535-018-1480-0.
   PubMed Web of Science ®Google Scholar
• Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–2885. doi: 10.1097/MIB.0000000000000561.
   PubMed Web of Science ®Google Scholar
• Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–2126. doi: 10.1097/MIB.0000000000000865.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease—a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44(11-12):1199–1212. doi: 10.1111/apt.13813.
   PubMed Web of Science ®Google Scholar
• Vivio EE, Kanuri N, Gilbertsen JJ, et al. Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice. J Crohns Colitis. 2016;10(4):402–409. doi: 10.1093/ecco-jcc/jjv226.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Rivera F, López-Gómez JM, et al. Increased prevalence of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2013;28(1):112–115. doi: 10.1093/ndt/gfs143.
   PubMed Web of Science ®Google Scholar
• Haas M, Spargo BH, Wit EJ, et al. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis. 2000;35(3):433–447. doi: 10.1016/s0272-6386(00)70196-x.
   PubMed Web of Science ®Google Scholar
• Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77(11):956–961. doi: 10.1038/ki.2010.89.
   PubMed Web of Science ®Google Scholar
• Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. Clin J Am Soc Nephrol. 2014;9(2):265–270. doi: 10.2215/CJN.04660513.
   PubMed Web of Science ®Google Scholar
• Pohjonen J, Nurmi R, Metso M, et al. Inflammatory bowel disease in patients undergoing renal biopsies. Clin Kidney J. 2019;12(5):645–651. doi: 10.1093/ckj/sfz004.
   PubMed Web of Science ®Google Scholar
• Yandian F, Caravaca-Fontán F, Herrera Hernandez LP, et al. Kidney diseases associated with inflammatory bowel disease: impact of chronic histologic damage, treatments, and outcomes. Kidney Int Rep. 2024;9(2):383–394. doi: 10.1016/j.ekir.2023.11.011.
   PubMed Web of Science ®Google Scholar
• Timmermans SA, Christiaans MH, Abdul-Hamid MA, et al. Granulomatous interstitial nephritis and Crohn’s disease. Clin Kidney J. 2016;9(4):556–559. doi: 10.1093/ckj/sfw041.
   PubMed Web of Science ®Google Scholar
• Comai G, Baraldi O, Cuna V, et al. Acute granulomatous interstitial nephritis and ulcerative colitis: a case report and literature review. Ital J Med. 2018;12(1):57–60. doi: 10.4081/itjm.2018.929.
   Google Scholar
• Schurder J, Buob D, Perrin P, et al. Acute interstitial nephritis: aetiology and management. Nephrol Dial Transplant. 2020;36(10):1799–1802. doi: 10.1093/ndt/gfz262.
   Web of Science ®Google Scholar
• Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638–647. doi: 10.1016/j.kint.2016.04.008.
   PubMed Web of Science ®Google Scholar
• Miao J, Sise ME, Herrmann SM. Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. Front Nephrol. 2022;2:1017921. doi: 10.3389/fneph.2022.1017921.
   PubMedGoogle Scholar
• Castro Corredor D, Sánchez de la Nieta MD, de Lara Simón IM. Acute tubulointerstitial nephritis in an HLA-B27-positive patient with axial spondyloarthritis being treated with adalimumab. Reumatol Clin (Engl Ed). 2019;15(3):179–181. doi: 10.1016/j.reuma.2017.03.012.
   PubMed Web of Science ®Google Scholar
• Sandys V, Moloney B, Lane L, et al. Granulomatous interstitial nephritis secondary to adalimumab therapy. Clin Kidney J. 2017;11(2):219–221. doi: 10.1093/ckj/sfx104.
   PubMed Web of Science ®Google Scholar
• Ota M, Iwai H, Imai K, et al. Acute tubulointerstitial nephritis associated with infliximab in a patient with Crohn’s disease. Intern Med. 2016;55(10):1367–1370. doi: 10.2169/internalmedicine.55.5834.
   PubMed Web of Science ®Google Scholar
• Sato T, Kawasaki Y, Ito A, et al. Infliximab-Induced tubulointerstitial nephritis with image findings of striated nephrogram in Crohn’s disease. Tohoku J Exp Med. 2018;245(3):149–152. doi: 10.1620/tjem.245.149.
   PubMed Web of Science ®Google Scholar
• Dal Buono A, Gabbiadini R, Alfarone L, et al. Sphingosine 1-phosphate modulation in inflammatory bowel diseases: keeping lymphocytes out of the intestine. Biomedicines. 2022;10(7):1735. doi: 10.3390/biomedicines10071735.
   PubMed Web of Science ®Google Scholar
• SPmC Entyvio (vedolizumab) Takeda Pharma A/S. Updated. July 2023.
   Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–1444. doi: 10.1093/ecco-jcc/jjw092.
   PubMed Web of Science ®Google Scholar
• Moss JG, Parry CM, Holt RCL, et al. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review. Eur J Med Res. 2022;27(1):61. doi: 10.1186/s40001-022-00687-y.
   PubMed Web of Science ®Google Scholar